Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness

Rhea-AI Summary

Aethlon Medical (NASDAQ:AEMD) is monitoring the current Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda and remains prepared to discuss potential investigational use of its Hemopurifier with global health and regulatory authorities.

The Hemopurifier is an investigational device designed to remove enveloped viruses. In a 2014 emergency-use case in Germany, a critically ill Ebola (Zaire strain) patient received a single 6.5-hour treatment, with reported viral load decline from ~400,000 to ~1,000 copies/mL and undetectable virus five days later. The FDA previously granted an IDE supplement enabling a regulatory pathway for investigational Hemopurifier use in Ebola patients in the U.S. The device remains investigational, and Aethlon will continue to monitor the outbreak and respond to clinician inquiries.

Positive

• Single 6.5-hour Hemopurifier treatment saw Ebola viral load drop from ~400,000 to ~1,000 copies/mL in 2014 case
• Testing estimated Hemopurifier captured about 242 million Ebola virions during 2014 emergency-use treatment
• FDA approved an IDE supplement in January 2015, creating a U.S. pathway for investigational Ebola use
• Hemopurifier previously available for Ebola patients via FDA expanded access emergency-use provisions

Negative

• Hemopurifier remains investigational for Ebola, with clinical experience described from a single prior patient

News Market Reaction – AEMD

+1.45%

1 alert

+1.45% Session close to close

$3.30M Market Cap

0.1x Rel. Volume

In the May 21 session, AEMD gained 1.45%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement reinforces Aethlon’s positioning of the Hemopurifier as a potential tool in outbre...

Analysis

This announcement reinforces Aethlon’s positioning of the Hemopurifier as a potential tool in outbreaks like the Bundibugyo Ebola situation, citing prior emergency-use data where viral load fell from 400,000 to 1,000 copies/mL and became undetectable within 5 days. It also recalls an FDA Investigational Device Exemption pathway for Ebola use. Investors may watch for concrete requests from clinicians or regulators, additional clinical data, and how this outbreak-focused messaging complements ongoing oncology and infectious-disease development plans.

Key Figures

Hemopurifier treatment duration: 6.5 hours Baseline viral load: 400,000 copies/mL Post-treatment viral load: 1,000 copies/mL +5 more

8 metrics

Hemopurifier treatment duration 6.5 hours Single emergency-use Hemopurifier session in 2014 Ebola case

Baseline viral load 400,000 copies/mL Ebola virus copies per milliliter before Hemopurifier treatment

Post-treatment viral load 1,000 copies/mL Ebola virus copies per milliliter after single treatment

Time to undetectable virus 5 days Ebola viral load became undetectable five days after treatment

Virions captured 242 million virions Quantitative estimate of Ebola particles captured by Hemopurifier

Ebola emergency-use case 1 patient Critically ill physician treated under emergency-use circumstances

IDE supplement date January 2015 FDA IDE supplement enabling investigational Ebola use in U.S.

ASN presentation date November 14, 2014 Hemopurifier Ebola case data presented at nephrology meeting

Historical Context

5 past events · Latest: Mar 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 24	Oncology trial safety	Positive	-6.1%	DSMB cleared cohort 2 and recommended advancing to cohort 3.
Mar 24	Clinical trial advance	Positive	-6.1%	Positive DSMB review allowed progression to final oncology trial cohort.
Mar 12	Strategic review	Positive	+4.8%	Maxim Group engaged to explore partnerships, M&A, and strategic options.
Feb 23	Investor conference	Neutral	-1.5%	Announcement of Emerging Growth Conference presentation and investor Q&A.
Feb 12	Earnings and update	Positive	-1.0%	Reported Q3 results, ~$7.0M cash, lower expenses, and R&D progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and operational updates have often seen negative or muted next-day reactions, while strategic/transaction-related news drew the clearest positive move.

Recent Company History

Over the last six months, Aethlon has focused on advancing its Hemopurifier programs and corporate positioning. On Feb 12, 2026, fiscal Q3 results with a cash balance of ~$7.0M and lower operating expenses were followed by a modest share decline. A March engagement of Maxim Group to evaluate strategic options on Mar 12, 2026 coincided with a +4.81% move. Two positive DSMB oncology updates on Mar 24, 2026 were met with a -6.09% reaction, underscoring a pattern where clinical progress has not consistently translated into immediate price strength. Today’s outbreak-preparedness communication fits that ongoing Hemopurifier narrative.

Key Terms

bundibugyo ebola virus, enveloped viruses, tumor-derived evs, investigational medical device, +4 more

8 terms

bundibugyo ebola virus medical

"current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo"

Bundibugyo ebola virus is one of the viruses in the ebola family that can cause severe, often life-threatening fever and bleeding in humans. For investors, it matters because outbreaks or the development of diagnostics, treatments and vaccines can rapidly change demand for medical supplies, influence biotech and pharmaceutical company values, and affect travel, insurance and public-health spending—similar to how a major product failure or breakthrough shifts market expectations.

enveloped viruses medical

"designed to remove enveloped viruses and tumor-derived EVs from circulation"

Enveloped viruses are viruses surrounded by a fragile, fatty outer coat that helps them enter and exit cells; think of the coat like a soap bubble that can be easily disrupted by detergents, heat, or certain disinfectants. For investors, whether a virus is enveloped matters because it shapes the types of vaccines, diagnostics, and treatments that are likely to work, influences manufacturing and safety requirements, and affects regulatory and public-health responses that can drive healthcare market demand.

tumor-derived evs medical

"designed to remove enveloped viruses and tumor-derived EVs from circulation"

Tumor-derived EVs are tiny packets released by cancer cells that carry bits of the cell’s molecular information, like proteins, genetic material, and signaling molecules. Think of them as biological postcards that reveal what the tumor is doing; investors care because they enable noninvasive tests, disease monitoring, and targeted delivery strategies, creating opportunities for diagnostics, drugs, and companion technologies with potential clinical and commercial value.

investigational medical device medical

"Hemopurifier is an investigational medical device designed to remove"

A device being used in clinical studies to gather safety and effectiveness data before it can be approved for general use. Think of it as a prototype being tested under close rules: results determine whether it can be sold, how large its potential market is, and how much regulatory and reimbursement risk remains—factors that directly affect a company’s future revenue and investment value.

expanded access regulatory

"available for Ebola patients through FDA expanded access emergency-use provisions"

Access that lets patients use an experimental drug or medical device outside of a formal clinical trial when no approved options are available. Think of it like allowing someone to test-drive a prototype car because they have no other transportation; for investors, expanded access can affect short-term demand, provide additional safety or usage information, and carry reputational or regulatory risks that may influence a company’s prospects and potential future sales.

investigational device exemption regulatory

"the U.S. Food and Drug Administration approved an Investigational Device Exemption"

An investigational device exemption (IDE) is a regulatory permission that allows a medical device maker to test an unapproved device in people so the device’s safety and effectiveness can be studied. For investors, an IDE matters because it marks a formal step toward regulatory approval—like getting a temporary test-drive permit—and influences clinical cost, timelines, and the likelihood a device will reach the market and generate revenue.

compassionate-use regulatory

"physician-directed emergency and compassionate-use procedures subject to applicable"

Compassionate-use is a regulatory pathway that lets seriously ill patients access an experimental drug or medical device before it receives full approval. For investors, it matters because such access can provide real-world safety and effectiveness information, generate early demand or publicity, and change expectations for a product’s commercial prospects, while not guaranteeing eventual regulatory approval or routine market sales.

emergency-use regulatory

"treated at Frankfurt University Hospital under emergency-use circumstances"

A temporary regulatory allowance that lets a medical product or treatment be used during a public health crisis before it has completed the usual full approval process. Think of it as a short-term pass that lets a new medicine or device reach patients quickly when waiting could cause harm. For investors, emergency-use status can unlock near-term sales and market access but carries higher regulatory and safety uncertainty that can affect a company’s future revenue and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology.

According to recent reports from the World Health Organization ("WHO") and other public health agencies, the current outbreak has been identified as involving the Bundibugyo strain of Ebola virus, a strain for which we are not aware of any approved treatments beyond supportive care, as of the date of this release. Health authorities continue to express concern regarding cross-border transmission and the potential for broader regional spread. Public health assessments, including regarding potential cross-border transmission, are evolving and subject to change.

Aethlon's Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. During the 2014 Ebola (Zaire strain) outbreak, the Hemopurifier was successfully administered to a critically ill Ugandan physician treated at Frankfurt University Hospital under emergency-use circumstances.

At the time Hemopurifier therapy was initiated, the physician was unconscious and suffering from multiple organ failure requiring mechanical ventilation, vasopressor support and continuous dialysis. Following a single 6.5-hour Hemopurifier treatment, the patient's viral load reportedly declined from approximately 400,000 Ebola virus copies per milliliter of blood to approximately 1,000 copies per milliliter of blood. The Ebola virus subsequently became undetectable five days following treatment. Testing performed after this treatment indicated that the Hemopurifier captured Ebola virus during therapy; quantitative estimates reported at the time, were approximately 242 million virions. The patient ultimately made recovered and returned home to Uganda.

That treatment data was presented at the American Society of Nephrology Annual Meeting on November 14, 2014 by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital.

In the United States, Hemopurifier therapy has previously been made available for Ebola patients through FDA expanded access emergency-use provisions applicable to life-threatening circumstances where alternative therapies may not be available. In January 2015, the U.S. Food and Drug Administration approved an Investigational Device Exemption ("IDE") supplement that established a regulatory pathway for the potential investigational use of Hemopurifier therapy in Ebola-infected individuals in the United States, subject to applicable institutional approvals and patient protection procedures.

Investigational use of medical technologies such as the Hemopurifier may proceed through physician-directed emergency and compassionate-use procedures subject to applicable hospital and regulatory oversight.

"We believe the current Ebola outbreak reinforces the ongoing need for broad-spectrum therapeutic approaches capable of addressing viral threats where approved drug therapies or vaccines may be limited," stated James B. Frakes, Chief Executive Officer of Aethlon Medical. "While the Hemopurifier remains investigational for Ebola treatment, the prior clinical experience on one patient in Germany demonstrated the potential for rapid viral reduction in a critically ill patient under emergency-use conditions."

The Company stated that it will continue to monitor the evolving Ebola situation and will respond to questions or requests from treating clinicians.

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for:

• The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and
• The treatment of life-threatening viruses not addressed with approved therapies.

The Hemopurifier is being developed under an open IDE for both indications.

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. For more information visit www.AethlonMedical.com and follow the company on LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this press release include but are not limited to statements regarding Aethlon's active monitoring of developments related to the current Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda; potential engagement and responsiveness to inquiries from treating clinicians and hospitals; potential interactions with global healthcare and regulatory authorities concerning potential investigational use of the Hemopurifier technology; the investigational status of the Hemopurifier for Ebola; references to prior emergency-use and FDA expanded access pathways; and the Company's development plans, regulatory pathway, and potential applications of the Hemopurifier, including its Breakthrough Device designation and ongoing development under an (IDE for oncology and life‑threatening viral indications. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitation, the need for and availability of physician-directed emergency or compassionate-use procedures; the requirement for and timing of applicable hospital and regulatory oversight, including institutional approvals and patient protection procedures; uncertainties inherent in investigational use of medical technologies; device performance, deficiencies, or immediate complications; clinical operations, logistics, and timing (including enrollment and access to eligible patients); the status of alternative therapies or supportive care; and the Company's development plans, regulatory pathway, and potential applications of the Hemopurifier. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Breakthrough Device designation expedites interaction with FDA but does not represent FDA clearance or approval and does not, by itself, establish safety or effectiveness. The findings described herein are preliminary in nature, have not been peer-reviewed, and may not be replicated in subsequent studies or clinical trials. Additional data would be required to assess safety and effectiveness.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-monitoring-current-ebola-outbreak-and-reaffirms-outbreakpandemic-preparedness-302778705.html

SOURCE Aethlon Medical, Inc.

FAQ

What did Aethlon Medical (NASDAQ:AEMD) announce on May 21, 2026 about the Ebola outbreak?

Aethlon Medical announced it is monitoring the Bundibugyo Ebola outbreak and remains prepared for potential investigational Hemopurifier use. According to Aethlon, it is ready to engage global health and regulatory authorities as public health assessments evolve in the Democratic Republic of the Congo and Uganda.

How is Aethlon Medical's Hemopurifier intended to work against viruses like Ebola (AEMD)?

The Hemopurifier is an investigational device designed to remove enveloped viruses and tumor-derived EVs from circulation. According to Aethlon, testing in a prior Ebola case indicated the cartridge captured virus during therapy, with quantitative estimates of approximately 242 million virions removed during treatment.

What were the 2014 Ebola patient results cited by Aethlon Medical for the Hemopurifier?

In 2014, a critically ill Ebola (Zaire strain) patient in Germany received a single 6.5-hour Hemopurifier treatment. According to Aethlon, viral load reportedly fell from about 400,000 to 1,000 copies/mL, became undetectable five days later, and roughly 242 million virions were estimated captured.

Is Aethlon Medical's Hemopurifier currently approved for Ebola treatment (AEMD)?

The Hemopurifier remains investigational for Ebola treatment and is not described as an approved therapy. According to Aethlon, use has occurred under FDA expanded access emergency-use provisions, and an IDE supplement provides a regulatory pathway for investigational use in Ebola-infected individuals in the United States.

How can Ebola patients potentially access Aethlon Medical's Hemopurifier in emergencies?

Hemopurifier therapy has previously been available through FDA expanded access emergency-use provisions for life-threatening situations. According to Aethlon, investigational use may proceed via physician-directed emergency and compassionate-use procedures, subject to hospital approvals and regulatory oversight, when alternative therapies may not be available.

What regulatory pathway exists in the U.S. for Aethlon Medical's Hemopurifier in Ebola cases?

In January 2015, the FDA approved an Investigational Device Exemption (IDE) supplement for Hemopurifier use in Ebola-infected individuals. According to Aethlon, this IDE supplement establishes a regulatory pathway for potential investigational therapy in the U.S., subject to institutional approvals and patient protection procedures.